drugset / Trial / NCT04634604
A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP
Phase 3
Terminated
16 enrolled
Jaeb Center for Health Research
National Eye Institute (NEI) · collabPediatric Eye Disease Investigator Group · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This randomized clinical trial will compare retinal outcomes with low-dose intravitreous bevacizumab (0.063 mg) versus laser photocoagulation as treatment for infants with type 1 retinopathy of prematurity (ROP). The study also will assess neurodevelopment, refractive error, visual acuity, and peripheral visual fields.
Timeline
- Start
- 2022-04-27
- Primary completion
- 2023-08-14
- Completion
- 2023-08-14
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of feasibility to recruit.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 0.063 mg | Other |